|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIR222HG |
Gene summary for MIR222HG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIR222HG | Gene ID | 104457406 |
| Gene name | miR222/221 cluster host gene | |
| Gene Alias | Lnc-Ang362 | |
| Cytomap | Xp11.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 104457406 | MIR222HG | P4_S8_cSCC | Human | Skin | cSCC | 1.04e-04 | 2.05e-01 | -0.3095 |
| 104457406 | MIR222HG | P5_S10_cSCC | Human | Skin | cSCC | 2.14e-26 | 5.15e-01 | -0.299 |
| 104457406 | MIR222HG | male-WTA | Human | Thyroid | PTC | 1.53e-07 | -7.34e-02 | 0.1037 |
| 104457406 | MIR222HG | PTC01 | Human | Thyroid | PTC | 5.28e-07 | 1.03e-01 | 0.1899 |
| 104457406 | MIR222HG | PTC03 | Human | Thyroid | PTC | 9.03e-05 | 3.33e-01 | 0.1784 |
| 104457406 | MIR222HG | PTC04 | Human | Thyroid | PTC | 5.68e-16 | 6.05e-01 | 0.1927 |
| 104457406 | MIR222HG | PTC05 | Human | Thyroid | PTC | 8.01e-22 | 1.22e+00 | 0.2065 |
| 104457406 | MIR222HG | PTC06 | Human | Thyroid | PTC | 1.16e-42 | 1.34e+00 | 0.2057 |
| 104457406 | MIR222HG | PTC07 | Human | Thyroid | PTC | 1.77e-22 | 6.83e-01 | 0.2044 |
| 104457406 | MIR222HG | ATC09 | Human | Thyroid | ATC | 7.58e-07 | 4.08e-01 | 0.2871 |
| 104457406 | MIR222HG | ATC11 | Human | Thyroid | ATC | 2.88e-05 | 7.40e-01 | 0.3386 |
| 104457406 | MIR222HG | ATC12 | Human | Thyroid | ATC | 1.75e-22 | 4.80e-01 | 0.34 |
| 104457406 | MIR222HG | ATC13 | Human | Thyroid | ATC | 2.62e-02 | -2.03e-01 | 0.34 |
| 104457406 | MIR222HG | ATC1 | Human | Thyroid | ATC | 2.56e-07 | 4.50e-01 | 0.2878 |
| 104457406 | MIR222HG | ATC2 | Human | Thyroid | ATC | 8.53e-10 | 5.61e-01 | 0.34 |
| 104457406 | MIR222HG | ATC3 | Human | Thyroid | ATC | 4.22e-16 | 9.58e-01 | 0.338 |
| 104457406 | MIR222HG | ATC4 | Human | Thyroid | ATC | 2.87e-30 | 6.02e-01 | 0.34 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |